Financial & competing interests disclosure
In the past year, the author has consulted with Teva and Sunovion and has spoken for AstraZeneca and Validus. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.